The global influenza diagnostics market size is estimated to be USD 843.5 million in 2021 and is expected to witness a CAGR of 7.89% during the forecast period. Increase in cases of influenza is a key driver for the growth of the global influenza diagnostics market. Additionally, growing research in the field of influenza and rise in demand for rapid disease diagnosis in the influenza diagnostics market are some of the other drivers propelling the market growth. Nevertheless, increasing expenditure in healthcare and inconsistency in test sensitivity and specificity in the diagnosis of influenza are expected to restrain the global market growth.
Based on test type, the market is categorized into traditional diagnostic tests, molecular diagnostic tests, and other molecular tests. In 2021, the traditional diagnostic tests segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is due to the increasing adoption of cost-effective and faster diagnostic tests worldwide. The molecular diagnostic segment is anticipated to grow at a profitable CAGR during the forecast period, due to the launch of new products and shift towards molecular diagnostics are the key factors driving the market worldwide.
Based on end user, the market is categorized into clinical laboratories, hospitals, and other end users. In 2021, the hospitals segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is due to the growing diagnosis of influenza diseases in hospitals worldwide. The clinical laboratories segment is anticipated to grow at a profitable CAGR during the forecast period, due to the high rate of penetration of these laboratories in developed regions.
In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the strong emphasis of the U.S. CDC on regulating the disease rates, increase in public awareness along with the accessibility of a wide range of diagnostic procedures, and accessibility of technologically advanced products in the region. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the adoption of new and developed technologies, increase in awareness among the people, high population mass, and substantial growth in disease burden, are the major factors in this region.Competitor Insights Some of the key players in the influenza diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland); Quidel Corporation (U.S.); Thermo Fisher Scientific (U.S.); Abbott Laboratories (U.S.); Hologic (U.S.); Becton, Dickinson, and Company (U.S.); DiaSorin S.p.A (Italy); Luminex Corporation (U.S.); Meridian Bioscience (U.S.); and GenMark Diagnostics (U.S.). The leading players operating in the influenza diagnostics industry are adopting various strategies including R&D investments, adoption of advanced techniques, new product launches, mergers & acquisitions, and regional expansions to capture a maximum revenue share.This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The influenza diagnostics market report is categorized into the following segments and subsegments:
By Test Type
Based on test type, the market is categorized into traditional diagnostic tests, molecular diagnostic tests, and other molecular tests. In 2021, the traditional diagnostic tests segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is due to the increasing adoption of cost-effective and faster diagnostic tests worldwide. The molecular diagnostic segment is anticipated to grow at a profitable CAGR during the forecast period, due to the launch of new products and shift towards molecular diagnostics are the key factors driving the market worldwide.
By End User
Based on end user, the market is categorized into clinical laboratories, hospitals, and other end users. In 2021, the hospitals segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is due to the growing diagnosis of influenza diseases in hospitals worldwide. The clinical laboratories segment is anticipated to grow at a profitable CAGR during the forecast period, due to the high rate of penetration of these laboratories in developed regions.
Regional Insights
In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the strong emphasis of the U.S. CDC on regulating the disease rates, increase in public awareness along with the accessibility of a wide range of diagnostic procedures, and accessibility of technologically advanced products in the region. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the adoption of new and developed technologies, increase in awareness among the people, high population mass, and substantial growth in disease burden, are the major factors in this region.Competitor Insights Some of the key players in the influenza diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland); Quidel Corporation (U.S.); Thermo Fisher Scientific (U.S.); Abbott Laboratories (U.S.); Hologic (U.S.); Becton, Dickinson, and Company (U.S.); DiaSorin S.p.A (Italy); Luminex Corporation (U.S.); Meridian Bioscience (U.S.); and GenMark Diagnostics (U.S.). The leading players operating in the influenza diagnostics industry are adopting various strategies including R&D investments, adoption of advanced techniques, new product launches, mergers & acquisitions, and regional expansions to capture a maximum revenue share.This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The influenza diagnostics market report is categorized into the following segments and subsegments:
Influenza Diagnostics Market, By Test Type (Revenue, USD Million, 2021 - 2029)
Traditional Diagnostic Tests
- RIDT
- Viral Culture
- DFA
- Serological Assays
Molecular Diagnostic Tests
- RT-PCR
- Isothermal Nucleic Acid Amplification Tests
- Transcription-Mediated Amplification-Based Assays
- Loop-Mediated Isothermal Amplification-Based Assays
Nucleic Acid Sequence-Based Amplification Tests
- Other INAAT Tests
- Other Molecular Tests
Influenza Diagnostics Market, By End User (Revenue, USD Million, 2021 - 2029)
- Clinical Laboratories
- Hospitals
- Other End Users
Influenza Diagnostics Market, By Region (Revenue, USD Million, 2021 - 2029)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of MEA
Table of Contents
1. Research Methodology
3. Executive Summary
4. Market Dynamics
5. Market Environment Analysis
6. COVID-19 Impact Analysis: Influenza Diagnostic Market
7. Market Analysis by Test type
8. Market Analysis by End use
9. Regional Market Analysis
10. North America Influenza Diagnostic Market
11. Europe Influenza Diagnostic Market
12. Asia Pacific Influenza Diagnostic Market
13. Latin America Influenza Diagnostic Market
14. MEA Influenza Diagnostic Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Quidel Corporation (U.S.)
- Thermo Fisher Scientific (U.S.)
- Abbott Laboratories (U.S.)
- Hologic (U.S.)
- Becton
- Dickinson
- Company (U.S.)
- DiaSorin S.p.A (Italy)
- Luminex Corporation (U.S.)
- Meridian Bioscience (U.S.)
- GenMark Diagnostics (U.S.)
